The FDA De Novo pathway is the route to market for a new medical device that is low or moderate risk but has no legally marketed predicate. If FDA grants the request, your device is classified as Class I or Class II, it can be marketed, and it can serve as a predicate for later 510(k) submissions. This guide covers who qualifies, how to file, what the request must contain, what it costs, how long it takes, and what happens afterward.
TL;DR
- De Novo is for novel devices with no predicate whose risks can be managed with general controls, or general and special controls. High-risk devices go to PMA instead.
- You can file after a 510(k) comes back "not substantially equivalent," or file directly when you determine no predicate exists. Electronic submission through eSTAR is now required.
- For FY 2027 (October 1, 2026 to September 30, 2027) the standard fee is $191,020 and the small business fee is $47,755.
- FDA's regulation sets a 120-day review window after acceptance. The MDUFA goal for a decision is 150 FDA days, so plan for more than four months.
- A granted De Novo creates a new device type. Your device becomes the predicate others can use, which has strategic value for IP and investors.
Table of Contents
- What the De Novo pathway is
- Who qualifies for De Novo
- Two ways to file
- What goes into a De Novo request
- Review timeline and fees
- De Novo vs. 510(k) vs. PMA
- Why FDA declines De Novo requests
- What happens after a grant
- Perspective
- How we help with commercialization around De Novo
- FAQ
- Sources
What the De Novo pathway is
A De Novo request is a risk-based marketing pathway for novel devices where general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness, but no legally marketed predicate exists. The authority sits in section 513(f)(2) of the FD&C Act. FDA issued a final rule implementing the process, published October 5, 2021 and effective January 3, 2022. Its regulations now live in 21 CFR Part 860, Subpart D.
Congress created the process in 1997 through FDAMA as an intermediate pathway between a 510(k) and a PMA. The 2012 FDASIA law then allowed a De Novo request without first submitting a 510(k).
The practical result matters more than the history. A new device without a predicate used to land in Class III by default. De Novo lets you ask FDA to classify it as Class I or II instead, which avoids a full PMA when the risk profile supports it.
Who qualifies for De Novo
A device is eligible when it meets all of these conditions, as FDA describes in its De Novo program training:
- The device type has not been classified by FDA. There is no applicable predicate through 510(k), and the type has not been approved under a PMA.
- The device presents low or moderate risk. FDA must make that determination under 21 U.S.C. 360c(f)(2)(A)(iv).
- The risks to health can be identified, and the general and special controls needed to mitigate them can be identified too.
Low risk alone is not enough
This is where first-time sponsors stumble. FDA's own training stresses that being low risk supports eligibility but does not by itself earn a grant. You must characterize each risk to health and propose reproducible controls, with at least one mitigation for every risk.
FDA also looks at benefit. Because De Novo devices are low to moderate risk, they may not need to confer as substantial a benefit to have a favorable benefit-risk profile. Even so, the agency considers these devices carefully because they may become predicates for future 510(k) devices. Your evidence needs to explain all risks and benefits well enough that controls can contain them.
Two ways to file
FDA recognizes two routes into a De Novo request:
- Option 1: after a 510(k). You submit a 510(k), receive a high-level not substantially equivalent (NSE) determination, and then file a De Novo request.
- Option 2: direct. You determine there is no legally marketed device on which to base substantial equivalence and file a De Novo request without a 510(k).
Option 2 saves time when the absence of a predicate is clear. It also puts the weight on your predicate search. The regulation requires a classification summary that, for devices without a prior 510(k), gives a complete description of the searches used to show no device of the same type exists. It also requires a list of potentially similar classification regulations, PMAs, HDEs, 510(k)s, EUAs or product codes, and a rationale for how your device differs from each.
If your search is thin, FDA can push back. A defensible record of what you searched and why each near match is different is worth the effort before you commit to Option 2.
What goes into a De Novo request
Sponsors prepare the request in eSTAR, the electronic Submission Template and Resource. FDA's guidance says eSTAR is the only electronic template currently available for De Novo, and electronic submissions have been required since October 1, 2025. The template walks you through the request with prompts and logic, includes integrated databases such as product codes and recognized consensus standards, and follows the structure of the review memo FDA reviewers use.
The request is identified as a "Request for Evaluation of Automatic Class III Designation" under 513(f)(2). According to FDA's De Novo page, contents include:
- Administrative information and a device description
- Classification information, including your recommended class
- A discussion of how general, or general and special, controls provide reasonable assurance of safety and effectiveness
- Clinical data, if applicable
- Nonclinical data, such as bench testing, sterilization, shelf life, biocompatibility, software, electrical safety, electromagnetic compatibility, and animal studies or literature where relevant
- A comparison of probable benefits with probable or anticipated risks
The risk and mitigation summary
The core of the request is a summary of risks and mitigations. It describes the probable risks to health that you know of or should reasonably know of, and pairs each with a proposed mitigation. If you recommend Class II, you must propose special controls for each risk. A simple way to organize this is a table with one row per risk: the hazard, the supporting evidence, the control, and the test that shows the control works.
Completeness at the door
FDA may refuse to accept a request that is ineligible or not complete enough for substantive review. The agency tells you within 15 days after receipt whether the request is accepted. A pre-submission meeting with the review division, plus an internal completeness check against the eSTAR prompts, reduces the chance of a refusal that costs you weeks.
Review timeline and fees
How long it takes
Once a request is accepted, FDA begins substantive review. Under 21 CFR 860.240, within 120 days of receipt of the request, or of additional information that results in acceptance, FDA reviews it and sends an order granting or declining it.
The real-world clock is looser than that. Under MDUFA V, FDA's performance goal for a De Novo decision (grant, decline or withdraw) is 150 FDA days for both FY 2026 and FY 2027, met in at least 70 percent of cases, with higher levels if earlier-year goals are met. If FDA sends an additional information (AI) request, that is an interim action: the review clock stops and resumes when you submit a complete response, which must carry the reference number of the original request. Your own response time therefore adds to the total.

What it costs
Most De Novo requests are subject to user fees. Exceptions include devices intended solely for pediatric use and certain government entities whose device will not be distributed commercially. The fee must be paid for FDA to begin its review, unless you qualify for a waiver or exemption.
| Fiscal year | Period | Standard fee | Small business fee |
|---|---|---|---|
| FY 2026 | Oct 1, 2025 to Sep 30, 2026 | $173,782 | $43,446 |
| FY 2027 | Oct 1, 2026 to Sep 30, 2027 | $191,020 | $47,755 |
The small business fee is 50 percent of the standard fee. A small business, counting affiliates, is one that reported $100 million or less in gross receipts or sales in its most recent federal income taxable year. Fees reset every October 1, so confirm the current figure on FDA's fee page before budgeting. Fees are only part of the cost. Testing, quality systems work and regulatory preparation usually cost far more.
De Novo vs. 510(k) vs. PMA
The three pathways differ by risk and by whether a predicate exists. FDA frames it this way: 510(k) is comparative, while PMA relies on an independent demonstration of safety and effectiveness.
| 510(k) | De Novo | PMA | |
|---|---|---|---|
| Risk level | Low to moderate | Low to moderate | High |
| Predicate needed | Yes | No | No |
| Standard of review | Substantial equivalence to a predicate | Reasonable assurance of safety and effectiveness with general and/or special controls | Independent demonstration of safety and effectiveness |
| Outcome | Clearance | Grant, new classification (Class I or II) | Approval (Class III) |
The choice is rarely free. If a valid predicate exists, 510(k) is the natural path. If your device is high risk, PMA applies. De Novo covers the middle: new, manageable risk, no predicate. The peer-reviewed literature on this pathway notes that critics have long pointed to 510(k) predicate chains with questionable safety records, which is part of why FDA reviews De Novo devices carefully, since they become future predicates.
For a wider view of how to choose among these routes alongside clinical, quality and reimbursement planning, see our medical device regulatory strategy guide.
Why FDA declines De Novo requests
Under 21 CFR 860.260, FDA may decline a request for reasons that include these grounds:
- The device does not meet the criteria for Class I or II
- The request contains a material falsehood or omission
- The labeling is noncompliant
- The product is not a device or combination product
- The type is already approved in a PMA or already classified
- An inspection finds controls inadequate
- A required nonclinical or clinical study fails regulatory conditions or is incomplete
- You make significant unsolicited changes after acceptance
Most of these are avoidable. The predicate search, the risk table, the study design and the labeling are all things you control before submission. Late design changes are the one that surprises teams: freeze the design that your data actually supports before you file.
What happens after a grant
When FDA grants a request, the device may be marketed once it complies with the applicable controls. A new classification regulation is established. FDA posts the granting order, publishes a Federal Register notice (including special controls for Class II), and voluntarily releases a decision summary. The notice comes within 30 days of the granting order.

Your device then becomes a predicate for future 510(k) submissions where applicable. For a company, that means followers can enter your category through 510(k) using your classification and special controls. It also means your data, decision summary and controls become the public benchmark for the category. Founders should plan IP accordingly: patents, trade secrets and first-mover brand position carry more weight once a competitor can use a streamlined route behind you. A freedom to operate analysis early in development helps confirm you can commercialize the device you intend to classify.
Perspective
Most De Novo conversations we have with university inventors and founders start with the regulatory form and should start earlier, with the commercial question: what does this device need to be, and who will pay for it?
Our team has worked inside major university technology transfer offices, led startups, reviewed federal grants and commercialized technology for industry. From that vantage point, we see De Novo as a strategy decision as much as a filing. A granted De Novo creates a category. That affects how you structure patents, how you license from the university, what investors will fund, and how you sequence trials against runway.
We encourage teams to tie regulatory milestones to funding strategy. The fee and the evidence package are significant, and non-dilutive sources such as SBIR and STTR grants can help pay for the work that builds a strong request. We also help teams prepare the commercial story investors want to see next to the regulatory plan, and we coordinate legal questions with our dedicated IP law partner so that licensing, patent position and spinout structure line up with the pathway you choose.
The strongest De Novo programs we see treat the predicate search, risk analysis and IP position as one connected workstream rather than three separate tasks.
the author
How we help with commercialization around De Novo
A De Novo request is one milestone in a longer path from lab to market. We advise universities, researchers, founders and companies on IP and patent strategy, licensing agreement structuring, spinout formation, funding strategy including SBIR/STTR, go-to-market planning and investor introductions, with a focus on life sciences and medical devices. If you are weighing a novel device and want the commercial and IP plan to fit the regulatory route, see our services.

For background reading, our guides on FDA regulatory consulting and life science commercialization explain how these pieces fit together. You can also start from the Tech Transfer Advisors home page.
FAQ
Do I need a 510(k) before a De Novo request?
No. Since 2012 you can submit a De Novo request directly when you determine no legally marketed device exists to base a substantial equivalence determination on. The other route is to file after a 510(k) returns a not substantially equivalent decision. Direct filing needs a well documented predicate search.
How long does a De Novo review take?
The regulation sets a 120-day review after acceptance, and FDA tells you within 15 days whether the request is accepted. The MDUFA V goal for a decision is 150 FDA days. Additional information requests stop the clock, so total calendar time depends partly on how quickly you respond.
How much does a De Novo request cost?
For FY 2027, the standard fee is $191,020 and the small business fee is $47,755. Fees change each October 1, and certain pediatric-only and government submissions are exempt. Check FDA's MDUFA fees page for the current amount before you file.
Can my device be used as a predicate after a grant?
Yes. A device classified as Class I or II through De Novo may be marketed and used as a predicate for future 510(k) submissions where applicable. FDA publishes the classification regulation, and for Class II the special controls, so later sponsors can build on them.
What format must a De Novo request be in?
Electronic, through eSTAR, unless FDA exempts you. The requirement has applied since October 1, 2025. The template guides you through the required sections and mirrors the structure FDA reviewers use.
Sources
- De Novo Classification Request, FDA
- De Novo Program Transcript, FDA CDRH Learn
- Medical Device De Novo Classification Process, Federal Register
- Factors to Consider When Making Benefit-Risk Determinations, FDA
- 21 CFR Part 860 Subpart D, eCFR
- 21 CFR 860.260, eCFR
- eSTAR Guidance for De Novo Requests, FDA
- FDA and Industry Actions on De Novo Classification Requests, FDA
- User Fees and Refunds for De Novo Classification Requests, FDA
- Medical Device User Fees, FDA
- Medical Device User Fee Rates for Fiscal Year 2026, Federal Register
- MDUFA Fees, FDA
- Medical Device Safety and the 510(k) Clearance Process, FDA
- Beyond the 510(k): The regulation of novel moderate-risk medical devices, PMC
Recommended
- Medical Device Regulatory Strategy: A U.S. Guide for Innovators
- FDA Regulatory Consulting: What It Covers and How to Hire
- Freedom to Operate Analysis: What It Is and How to Run One
Made with BabyLoveGrowth to grow visibility across Google and AI search
